EW logo

Edwards Lifesciences Corporation (EW)

$107.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EW

Market cap

$61.59B

EPS

1.77

P/E ratio

48.9

Price to sales

7.54

Dividend yield

--

Beta

0.846171

Price on EW

Previous close

$107.15

Today's open

$107

Day's range

$104.94 - $108

52 week range

$74.66 - $108

Profile about EW

CEO

Bernard J. Zovighian

Employees

16000

Headquarters

Irvine, CA

Exchange

New York Stock Exchange

Shares outstanding

575000000

Issue type

Common Stock

EW industries and sectors

Healthcare

Medical Equipment & Supplies

News on EW

Edwards Lifesciences Q3 Earnings Call Highlights

Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.

news source

MarketBeat • Nov 7, 2026

news preview

Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs

EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing t.

news source

Business Wire • Nov 4, 2026

news preview

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

news source

Benzinga • Nov 4, 2026

news preview

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?

Heavy AI capex hit free cash flows at Alphabet and Meta, while Microsoft and Amazon faced mounting concerns over compressed margins, search cannibalization, and agentic commerce disruption. With Apple reporting on an unusual Monday schedule, nine S&P 500 firms confirmed delayed reporting dates, a historical indicator of potential bad news ahead. This marks the second week of Q3 earnings season, with 2,465 companies expected to report and overall S&P 500 EPS growth holding at a robust 29.5%.

news source

Seeking Alpha • Nov 3, 2026

news preview

Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

Edwards Lifesciences NYSE: EW highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic stenosis. Get Edwards Lifesciences alerts:Sign UpCLASP IITR meets six-month primary endpoint Charlie Davidson, chief of cardiology and medical director of the Bluhm Cardiovascular Institute and global co-principal investigator of CLASP IITR, said the trial met its six-month composite primary endpoint.

news source

MarketBeat • Nov 3, 2026

news preview

CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained through one year. The data were presented during late-breaking clinical trial sessions at Transcatheter Cardi.

news source

Business Wire • Nov 2, 2026

news preview

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patients with at-risk features. The late-breaking results were presented at Transcatheter Cardiovascular Th.

news source

Business Wire • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Edwards Lifesciences Corporation

Open an M1 investment account to buy and sell Edwards Lifesciences Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EW on M1